Intuitive Surgical reported quarterly revenue of $2.87 billion, up 18.8% year-over-year, and delivered adjusted earnings per share of $2.53, beating consensus estimates by $0.26. The company’s net margin reached 28.4%, while return on equity stood at 15.1%. Despite this outperformance, management issued guidance below street expectations for the current fiscal year, citing softness in elective procedure volumes and continued supply-chain pressures on instrument production. Investors will watch how management balances capital deployment for R&D versus share repurchases given the cautious outlook.

Alpha Cubed Investments LLC boosted its stake by 13.0%, acquiring an additional 10,677 shares to reach 92,600 shares, representing 1.4% of its portfolio and making ISRG its 19th largest holding. Valley Wealth Managers raised its position by 52.7% to 4,084 shares, Tandem Investment Advisors added 396 shares to reach 9,219 shares, and Strategic Advisors increased holdings by 63.3% to 10,397 shares. These moves follow a pattern in which institutional ownership now exceeds 83%, underscoring growing confidence among active managers in surgical robotics long term.

The FDA granted clearance for the da Vinci 5 system in select advanced cardiac procedures, opening a large new addressable market for both system sales and recurring consumables. Following this milestone, TD Cowen upgraded the stock to strong-buy, while Barclays reaffirmed its buy rating and HSBC lifted its target. However, Evercore ISI trimmed its target, and some coverage pieces suggest re-rating shares after recent weakness. This divergence in price targets creates mixed near-term sentiment but reinforces conviction in the company’s longer-term growth runway.